Open AccessCost-utility analysis of factor VIII diet therapies prepared using blood plasma vs. recombinant technique for patients with hemophilia A
Author(s) -
Farhad Lotfi,
Hamid Talebianpour,
Khosro Keshavarz,
Fatemeh Emadi,
Mohammad Reza Fayyazı Bordbar,
Peivand Bastani
Publication year - 2020
Publication title -
daru
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.645
H-Index - 42
eISSN - 2008-2231
pISSN - 1560-8115
DOI - 10.1007/s40199-020-00347-8
Subject(s) - medicine , cost–utility analysis , recombinant dna , univariate analysis , cost effectiveness analysis , cost effectiveness , univariate , purchasing power parity , statistics , multivariate analysis , risk analysis (engineering) , mathematics , biochemistry , chemistry , macroeconomics , multivariate statistics , exchange rate , economics , gene
Hemophilia is known as one of the most common coagulation disorders whose treatment costs are particularly high in developing countries, and about 90% of them are related to factor VIII (FVIII) and direct medical costs (DMCs). Thus, the present study aimed to analyze cost-utility of two FVIII diet therapies prepared using blood plasma and recombinant technique.